148 related articles for article (PubMed ID: 32277617)
21. Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125.
Wang N; Xiao F; Shao H; Shi S; Zhou Y
J Healthc Eng; 2022; 2022():8401202. PubMed ID: 35368946
[TBL] [Abstract][Full Text] [Related]
22. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
[TBL] [Abstract][Full Text] [Related]
24. Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease.
Wang J; Zhu M; Zhou X; Wang T; Zhang J
J BUON; 2020; 25(5):2287-2292. PubMed ID: 33277847
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
26. Olaparib and paclitaxel in combination with carboplatin in treatment of ovarian cancer: influence on disease control.
Zhang H; Zhang Y
Am J Transl Res; 2022; 14(1):468-475. PubMed ID: 35173866
[TBL] [Abstract][Full Text] [Related]
27. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
28. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
29. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of chemoradiotherapy combined with bevacizumab in patients with nasopharyngeal carcinoma: A comparative study.
Zhang F; Yuan T; Gao M
J BUON; 2019; 24(3):1252-1258. PubMed ID: 31424687
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
Gao Y; Wang J; Zhou Y; Sheng S; Qian SY; Huo X
Sci Rep; 2018 Feb; 8(1):2732. PubMed ID: 29426902
[TBL] [Abstract][Full Text] [Related]
32. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
33. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
[TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma.
Qiu Y; He J; Chen X; Huang P; Hu K; Yan H
Clin Chim Acta; 2018 May; 480():186-192. PubMed ID: 29438681
[TBL] [Abstract][Full Text] [Related]
37. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).
Farolfi A; Petrone M; Scarpi E; Gallà V; Greco F; Casanova C; Longo L; Cormio G; Orditura M; Bologna A; Zavallone L; Ventriglia J; Franzese E; Loizzi V; Giardina D; Pigozzi E; Cioffi R; Pignata S; Giorda G; De Giorgi U
Target Oncol; 2018 Aug; 13(4):469-479. PubMed ID: 29948780
[TBL] [Abstract][Full Text] [Related]
39. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
40. CT combined with tumor markers in the diagnosis and prognosis of hepatocellular carcinoma.
Huang X; Li J; Wang F; Hao M
J BUON; 2018; 23(4):985-991. PubMed ID: 30358203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
